New Progestogens

  title={New Progestogens},
  author={R{\'e}gine Sitruk-Ware},
  journal={Drugs \& Aging},
The progestins have different pharmacological properties depending upon the parent molecule, usually testosterone or progesterone, from which they are derived. Very small structural changes in the parent molecule may induce considerable differences in the activity of the derivative. In postmenopausal women with an intact uterus, progestins are used in combination with estrogen as hormone-replacement therapy (HRT). The development of new generations of progestins with improved selectivity… 
36 Citations
The “newer” progestogens and postmenopausal hormone therapy (HRT)
  • A. Schindler
  • Medicine, Biology
    The Journal of Steroid Biochemistry and Molecular Biology
  • 2014
The evolution of progesterone receptor ligands
Ligands for PR were developed into drugs, and their evolution can be crudely divided into three periods: drug‐like steroids that mimic the gestational properties of progesterone; drug-like steroids with different properties from progester one and expanded therapeutic applications; and non‐steroidal PR ligands with improved selectivity and modulator properties and further expand therapeutic applications.
Not All Progestins are Created Equally: Considering Unique Progestins Individually in Psychobehavioral Research
It is argued that accounting for unique aspects of progestins is necessary for a comprehensive understanding of the influence of HCs on women and a better understanding of these differences may clarify previous research and inform future studies.
Dienogest, a synthetic progestin, inhibits the proliferation of immortalized human endometrial epithelial cells with suppression of cyclin D1 gene expression.
It is suggested that dienogest directly inhibits the proliferation of human endometrial epithelial cells with suppression of cyclin D1 gene expression.
Combination of Drospirenone and Estradiol: A New Hormone Therapy in Postmenopausal Women
  • J. Huber
  • Biology, Medicine
    Women's health
  • 2007
The problems that arise in connection with the menopause have been treated for many years with various hormone-replacement therapy formulations. The spironolactone derivative drospirenone is a novel


Progestogens in hormonal replacement therapy: new molecules, risks, and benefits
Complying with the classic contraindications of HRT and selecting molecules devoid of estrogenic, androgenic, or glucocorticoid effect should allow a larger use of the progestins without any major drawback.
The pharmacological profile of a novel norpregnance progestin (trimegestone).
Results show trimegestone to have a favorable pharmacological profile with potent progestomimetic activity, and to be not associated with any unwanted pharmacological effects.